| M | T | O | T | F | L | S |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 | ||||||
Retina : nature.com subject feeds
- Toxicity analysis of gold nanoparticle formulations used for intraocular applications
- Loss of adult visual responses by developmental BPA exposure is correlated with altered estrogenic signaling
- Modulation of microglial phagocytosis via the GAS6-MERTK pathway regulates pathological angiogenesis in the mouse oxygen-induced retinopathy model
- Reln-Dab1 pathway mitigates retinal ganglion cell apoptosis in retinal ischemia-reperfusion injury
- The TP53 Arg72Pro polymorphism predicts visual and neurodegenerative outcomes in retinal detachment
OphthalmologyTimes articles
- Resident surgeons perform ISBCS with similar safety and accuracy as consultants
- FLIO and the brain: Making the invisible visible with Robert Sergott, MD
- Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
- SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
- Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
- EssilorLuxottica set to acquire Optegra clinics
- FDA approves prednisolone acetate ophthalmic suspension for treating steroid-responsive ocular inflammation
- HIV drug lamivudine shows promise in treating diabetic macular edema
- Formosa Pharmaceuticals grants Harrow US commercial rights to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia
- Qlaris Bio announces development of QLS-111-FDC